Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

(AP) — Gilead Sciences Inc. (GILD) on Wednesday reported third-quarter net income of $1.25 billion. On a per-share basis, the Foster City, California-based company said it had net income of $1.

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said ... was made in consultation with the U.S. health regulator, the company said. The U.S. Food and Drug Administration had granted ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.